Plant natural products in anticancer drug discovery

Current Organic Chemistry

Volumn 14, Issue 16, 2010, Pages 1781-1791

  Grothaus, Paul G ^a   Cragg, Gordon M ^a   Newman, David J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Anticancer; Antitumor; Endophytes; Plant derived natural products; Targeted agents

Indexed keywords

DRUG PRODUCTS; FUNGI;

ANTI-CANCER AGENTS; ANTI-TUMORS; ANTICANCER; ANTICANCER DRUG DISCOVERY; DRUG DISCOVERY; ENDOPHYTE; MOLECULAR TARGETS; NATURAL PRODUCTS; PLANT-DERIVED NATURAL PRODUCT; TARGETED AGENT;

DISEASES;

EID: 78649965172     PISSN: 13852728     EISSN: None     Source Type: Journal    
DOI: 10.2174/138527210792927708     Document Type: Article

References (93)

1. Borchardt, J. K. The Beginnings of Drug Therapy: Ancient Mesopotamian Medicine. Drug News Perspect., 2002, 15, 187-192.
2. nd Ed. CRC Press: Boca Raton, FL, 1999; p. 512.
3. Kapoor, L. D. Handbook of Ayurvedic Medicinal Plants: Herbal Reference Library. CRC Press: Boca Raton, FL, 2000; p. 424.
4. Dev, S. Ancient-modern concordance in Ayurvedic plants: some examples. Environ. Health Perspect., 1999, 107, 783-789.
5. Hamilton, G. R.; Baskett, T. F. In the arms of Morpheus the development of morphine for postoperative pain relief. Can. J. Anaesth. J., 2000, 47, 367-374.
6. Cassady, J. M.; Douros, J.D. Anticancer Agents Based on Natural Product Models. Academic Press: New York, 1980.
7. Newman, D. J.; Cragg, G. M. Natural Product Scaffolds as Leads to Drugs. Future. Med. Chem., 2009, 1, 1415-1427.
8. Newman, D. J.; Cragg, G. M.; Holbeck, S.; Sausville, E. A. Natural products and derivatives as leads to cell cycle pathway targets in cancer chemotherapy. Curr. Cancer Drug Targets, 2002, 2, 279-308.
9. Newman, D. J.; Cragg, G. M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod., 2007, 70, 461-477.
10. Newman, D. J.; Cragg, G. M.; Snader, K. M. Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod., 2003, 66, 1022-1037.
11. Bailly, C. Ready for a comeback of natural products in oncology. Biochem. Pharmacol., 2009, 77, 1447-1457.
12. Balunas, M. J.; Kinghorn, A. D. Drug discovery from medicinal plants. Life Sci., 2005, 78, 431-41.
13. Butler, M. S. Natural products to drugs: natural product-derived compounds in clinical trials. Nat. Prod. Rep., 2008, 25, 475-516.
14. Cragg, G. M.; Newman, D. J. Plants as a source of anti-cancer agents. J. Ethnopharmacol., 2005, 100, 72-79.
15. Hostettmann, K.; Marston, A. The search for new drugs from higher plants. Chimia 2007, 61, 322-326.
16. Hostettmann, K.; Marston, A. Plants as a still unexploited source of new drugs. Nat. Prod. Commun., 2008, 3, 1307-1315.
17. Kinghorn, A. D.; Chin, Y.-W.; Swanson, S. M. Discovery of natural product anticancer agents from biodiverse organisms. Curr. Opin. Drug. Discov. Devel., 2009, 12, 189-196.
18. Li, J. W.-H.; Vederas, J. C. Drug discovery and natural products: end of an era or an endless frontier? Science 2009, 325, 161-5.
19. Potterat, O.; Hamburger, M. Drug discovery and development with plantderived compounds. Prog. Drug Res., 2008, 65, 45, 47-118.
20. Cragg, G. M.; Newman, D. J. Nature: A vital source of leads for anticancer drug development. Phytochem. Rev., 2009, 8, 313-331.
21. Gueritte, F.; Fahy, J. The Vinca Alkaloids. In Anticancer Agents from Natural Products, Cragg, G. M.; Kingston, D. G. I.; Newman, D. J., Eds. CRC Press LLC: Boca Raton, Fla, 2005; pp 123-135.
22. Bennouna, J.; Campone, M.; Delord, J. P.; Pinel, M.-C. Vinflunine: a novel antitubulin agent in solid malignancies. Expert. Opin. Investig. Drugs., 2005, 14, 1259-1267.
23. Lee, K.; Xiao, Z. Antitumor agents 240. Podophyllotoxins and Analogs. In Anticancer Agents from Natural Products, Cragg, G. M.; Kingston, D. G. I.; Newman, D. J., Eds. CRC Press LLC: Boca Raton, Fla, 2005; pp 71-87.
24. Kingston, D. Tubulin-Interactive Natural Products as Anticancer Agents (1). J. Nat. Prod., 2009.
25. Kingston, D. G. Taxol and its Analogs. In Anticancer Agents from Natural Products Cragg, G. M.; Kingston, D. G. I.; Newman, D. J., Eds. CRC Press LLC: Boca Raton, Fla, 2005; pp 89-122.
26. Kingston, D. G. I.; Newman, D. J. Taxoids: cancer-fighting compounds from nature. Curr. Opin. Drug. Discov. Dev., 2007, 10, 130-44.
27. Cragg, G. M.; Newman, D. J. A Tale of Two Tumor Targets: Topoisomerase I and Tubulin. The Wall and Wani Contribution to Cancer Chemotherapy. J. Nat. Prod., 2004, 67, 232-244.
28. Rahier, N. J.; Thomas, C. J.; Hecht, S. M. Camptothecin and its analogs. In Anticancer Agents from Natural Products, Cragg, G. M.; Kingston, D. G. I.; Newman, D. J., Eds. CRC Press LLC: Boca Raton, Fla, 2005; pp 5-21.
29. Itokawa, H.; Wang, X.; Lee, K.-H. Homoharringtonine and related compounds. In Anticancer Agents from Natural Products, Cragg, G. M.; Kingston, D. G. I.; Newman, D. J., Eds. CRC Press LLC: Boca Raton, Fla, 2005; pp 47-70.
30. Auclair, C. Multimodal action of antitumor agents on DNA: the ellipticine series. Arch. Biochem. Biophys., 1987, 259, 1-14.
31. Hamburger, M.; Marston, A.; Hostettmann, K. Search for new drugs of plant origin. In Advances in drug research, Testa, B., Ed. Academic Press: 1991; Vol. 20, pp 167-215.
32. Li, Q.; Sham, H. L. Discovery and development of antimitotic agents that inhibit tubulin polymerisation for the treatment of cancer. Expert. Opin. Ther. Pat., 2002, 12, 1663-1702.
33. Pinney, K. G.; Jelinek, C.; Edvardsen, K.; Chaplin, D. J.; Pettit, G. R. The discovery and development of the combretastatins. In Anticancer Agents from Natural Products, Cragg, G. M.; Kingston, D. G. I.; Newman, D. J., Eds. CRC Press LLC: Boca Raton, Fla, 2005; pp 23-46.
34. Christian, M. C.; Pluda, J. M.; Ho, P. T. C.; Arbuck, S. G.; Murgo, A. J.; Sausville, E. A. Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute. Semin. Oncol., 1997, 24, 219-240.
35. Fischer, P. M.; Gianella-Borradori, A. Recent progress in the discovery and development of cyclin-dependent kinase inhibitors. Expert. Opin. Investig. Drugs., 2005, 14, 457-477.
36. Mayer, F.; Mueller, S.; Malenke, E.; Kuczyk, M.; Hartmann, J. T.; Bokemeyer, C. Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines. Investig. New. Drugs., 2005, 23, 205-211.
37. Meijer, L.; Raymond, E. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc. Chem. Res., 2003, 36, 417-425.
38. Chang, Y. T.; Gray, N. S.; Rosania, G. R.; Sutherlin, D. P.; Kwon, S.; Norman, T. C.; Sarohia, R.; Leost, M.; Meijer, L.; Schultz, P. G. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chem. Biol., 1999, 6, 361-375.
39. Hampson, P.; Chahal, H.; Khanim, F.; Hayden, R.; Mulder, A.; Assi, L. K.; Bunce, C. M.; Lord, J. M. PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. Blood 2005, 106, 1362-1368.
40. Hampson, P.; Kavanagh, D.; Smith, E.; Wang, K.; Lord, J. M.; Ed Rainger, G. The anti-tumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-delta dependent manner. Cancer. Immunol. Immunother., 2008, 57, 1241-1251.
41. Wang, X.; Matta, R.; Shen, G.; Nelin, L. D.; Pei, D.; Liu, Y. Mechanism of triptolide-induced apoptosis: Effect on caspase activation and Bid cleavage and essentiality of the hydroxyl group of triptolide. J. Mol. Med., 2006, 84, 405-415.
42. Yu, T.; Floss, H. G., Ansamitocins (maytansinoids). In Anticancer Agents from Natural Products, Cragg, G. M.; Kingston, D. G. I.; Newman, D. J., Eds. CRC Press LLC: Boca Raton, Fla, 2005; pp 321-337.
43. Ikeda, H.; Hideshima, T.; Fulciniti, M.; Lutz, R. J.; Yasui, H.; Okawa, Y.; Kiziltepe, T.; Vallet, S.; Pozzi, S.; Santo, L.; Perrone, G.; Tai, Y.-T.; Cirstea, D.; Raje, N. S.; Uherek, C.; Dälken, B.; Aigner, S.; Osterroth, F.; Munshi, N.; Richardson, P.; Anderson, K. C. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138- positive multiple myelom cells in vitro and in vivo. Clin. Cancer. Res., 2009, 15, 4028-4037.
44. Polson, A. G.; Sliwkowski, M. X. Toward an effective targeted chemotherapy for multiple myeloma. Clin. Cancer. Res., 2009, 15, 3906-7.
45. Senter, P. D. Potent antibody drug conjugates for cancer therapy. Curr. Opin. Chem. Biol., 2009, 13, 235-244.
46. Stephan, J.-P.; Chan, P.; Lee, C.; Nelson, C.; Elliott, J. M.; Bechtel, C.; Raab, H.; Xie, D.; Akutagawa, J.; Baudys, J.; Saad, O.; Prabhu, S.; Wong, W. L. T.; Vandlen, R.; Jacobson, F.; Ebens, A. Anti-CD22-MCC-DM1 and MCMMAF conjugates: impact of assay format on pharmacokinetic parameters determination. Bioconjug. Chem., 2008, 19, 1673-1683.
47. Denmeade, S. R.; Jakobsen, C. M.; Janssen, S.; Khan, S. R.; Garrett, E. S.; Lilja, H.; Christensen, S. B.; Isaacs, J. T. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J. Natl. Cancer. Inst., 2003, 95, 990-1000.
48. Low, P. S.; Kularatne, S. A. Folate-targeted therapeutic and imaging agents for cancer. Curr. Opin. Chem. Biol., 2009, 13, 256-262.
49. Cuendet, M.; Pezzuto, J. M. Antitumor activity of bruceantin: an old drug with new promise. J. Nat. Prod., 2004, 67, 269-272.
50. Xiao, Z.; Hao, Y.; Liu, B.; Qian, L. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk. Lymphoma., 2002, 43, 1763-8.
51. Meijer, L.; Skaltsounis, A. L.; Magiatis, P.; Polychronopoulos, P.; Knockaert, M.; Leost, M.; Ryan, X. P.; Vonica, C. A.; Brivanlou, A.; Dajani, R.; Crovace, C.; Tarricone, C.; Musacchio, A.; Roe, S. M.; Pearl, L.; Greengard, P. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem. Biol., 2003, 10, 1255-1266.
52. Cohen, P.; Goedert, M. GSK3 inhibitors: development and therapeutic potential. Nat. Rev. Drug. Discov., 2004, 3, 479-487.
53. Knockaert, M.; Blondel, M.; Bach, S.; Leost, M.; Elbi, C.; Hager, G. L.; Nagy, S. R.; Han, D.; Denison, M.; Ffrench, M.; Ryan, X. P.; Magiatis, P.; Polychronopoulos, P.; Greengard, P.; Skaltsounis, L.; Meijer, L. Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediate the antiproliferative effects of indirubins. Oncogene 2004, 23, 4400-4412.
54. Denison, M. S.; Nagy, S. R. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu. Rev. Pharmacol. Toxicol., 2003, 43, 309-334.
55. Polychronopoulos, P.; Magiatis, P.; Skaltsounis, A. L.; Myrianthopoulos, V.; Mikros, E.; Tarricone, A.; Musacchio, A.; Roe, S. M.; Pearl, L.; Leost, M.; Greengard, P.; Meijer, L. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclindependent kinases. J. Med. Chem., 2004, 47, 935-946.
56. Lee, S. K.; Cui, B.; Mehta, R. R.; Kinghorn, A. D.; Pezzuto, J. M. Cytostatic mechanism and antitumor potential of novel 1H-cyclopenta[b]benzofuran lignans isolated from Aglaia elliptica. Chem. Biol. Interact., 1998, 115, 215-228.
57. Lucas, D. M.; Edwards, R. B.; Lozanski, G.; West, D. A.; Shin, J. D.; Vargo, M. A.; Davis, M. E.; Rozewski, D. M.; Johnson, A. J.; Su, B.-N.; Goettl, V. M.; Heerema, N. A.; Lin, T. S.; Lehman, A.; Zhang, X.; Jarjoura, D.; Newman, D. J.; Byrd, J. C.; Kinghorn, A. D.; Grever, M. R. The novel plantderived agent silvestrol has B-cell selective activity in chronic lymphocyticleukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood, 2009, 113, 4656-4666.
58. Cencic, R.; Carrier, M.; Galicia-Vázquez, G.; Bordeleau, M.-E.; Sukarieh, R.; Bourdeau, A.; Brem, B.; Teodoro, J. G.; Greger, H.; Tremblay, M. L.; Porco, J. A.; Pelletier, J. Antitumor activity and mechanism of action of the cyclopenta[ b]benzofuran, silvestrol. PLoS ONE 2009, 4, e5223.
59. Sun, J.; Blaskovich, M. A.; Jove, R.; Livingston, S. K.; Coppola, D.; Sebti, S. M. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene., 2005, 24, 3236-3245.
60. Kupchan, S. M.; Anderson, W. K.; Bollinger, P.; Doskotch, R. W.; Smith, R. M.; Renauld, J. A. S.; Schnoes, H. K.; Burlingame, A. L.; Smith, D. H. Tumor inhibitors. XXXIX. Active principles of Acnistus arborescens. Isolation and structural and spectral studies of withaferin a and withacnistin. J. Org. Chem., 1969, 34, 3858-3866.
61. Sun, J.; Blaskovich, M. A.; Jove, R.; Livingston, S. K.; Coppola, D.; Sebti, S. M. Cucurbitacin Q: A selective STAT3 activation inhibitor with potent antitumor activity (Oncogene (2005) 24, (3236-3245) DOI: 10.1038/sj.onc.1208470)). Oncogene., 2008, 27, 1344.
62. Cichewitz, R. H.; Kouzi, S. A. Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection. Med. Res. Rev., 2004, 24, 90-114.
63. Couch, R. D.; Browning, R. G.; Honda, T.; Gribble, G. W.; Wright, D. L.; Sporn, M. B.; Anderson, A. C. Studies on the reactivity of CDDO, a promising new chemopreventive and chemotherapeutic agent: implications for a molecular mechanism of action. Bioorg. Med. Chem. Lett., 2005, 15, 2215-2219.
64. Melichar, B.; Konopleva, M.; Hu, W.; Melicharova, K.; Andreeff, M.; Freedman, R. S. Growth-inhibitory effect of a novel synthetic triterpenoid, 2- cyano-3,12-dioxoolean-1,9-dien-28-oic acid, on ovarian carcinoma cell lines not dependent on peroxisome proliferator-activated receptor-gamma expression. Gynecol. Oncol., 2004, 93, 149-154.
65. Li, Y.; Sun, X.; LaMont, J. T.; Pardee, A. B.; Li, C. J. Selective killing of cancer cells by beta -lapachone: direct checkpoint activation as a strategy against cancer. Proc. Natl. Acad. Sci. USA, 2003, 100, 2674-2678.
66. Choi, B. T.; Cheong, J.; Choi, Y. H. beta-Lapachone-induced apoptosis is associated with activation of caspase-3 and inactivation of NF-kappaB in human colon cancer HCT-116 cells. Anticancer. Drugs., 2003, 14, 845-850.
67. Ravelo, A. G.; Estévez-Braun, A.; Chávez-Orellana, H.; Pérez-Sacau, E.; Mesa-Siverio, D. Recent studies on natural products as anticancer agents. Curr. Top. Med. Chem., 2004, 4, 241-65.
68. Mi, Q.; Lantvit, D.; Reyes-Lim, E.; Chai, H.; Phifer, S. S.; Wani, M. C.; Wall, M. E.; Tan, G. T.; Cordell, G. A.; Farnsworth, N. R.; Kinghorn, A. D.; Pezzuto, J. M. Apoptotic anticancer effect of alvaradoin E isolated from Alvaradoa haitiensis. Anticancer. Res., 2005, 25, 779-787.
69. Pettit, G. R.; Gaddamidi, V.; Herald, D. L.; Singh, S. B.; Cragg, G. M.; Schmidt, J. M.; Boettner, F. E.; Williams, M.; Sagawa, Y. Antineoplastic agents, 120. Pancratium littorale. J. Nat. Prod., 1986, 49, 995-1002.
70. Pettit, G.; Melody, N.; Herald, D. Antineoplastic agents. 450. Synthesis of (+)-pancratistatin from (+)-narciclasine as relay. J. Org. Chem., 2001, 66, 2583-2587.
71. Kim, S.; Ko, H.; Kim, E.; Kim, D. Stereocontrolled total synthesis of pancratistatin. Org. Lett., 2002, 4, 1343-1345.
72. Kekre, N.; Griffin, C.; McNulty, J.; Pandey, S. Pancratistatin causes early activation of caspase-3 and the flipping of phosphatidyl serine followed by rapid apoptosis specifically in human lymphoma cells. Cancer. Chemother. Pharmacol., 2005, 56, 29-38.
73. Griffin, C.; McNulty, J.; Hamm, C.; Pandey, S. Pancratistatin a novel highly selective anti-cancer agent that induces apoptosis by the activation of membrane- Fas-receptor associated caspase-3. In Cell apoptosis research trends, Zhang, C. V.; Figgins, H. C., Eds. Nova Science Publishers: Hauppauge, NY, 2007; pp 93-107.
74. Pettit, G. R.; Melody, N.; Herald, D. L. Antineoplastic agents. 511. Direct phosphorylation of phenpanstatin and pancratistatin. J. Nat. Prod., 2004, 67, 322-327.
75. Shnyder, S. D.; Cooper, P. A.; Millington, N. J.; Gill, J. H.; Bibby, M. C. Sodium pancratistatin 3,4-O-cyclic phosphate, a water-soluble synthetic derivative of pancratistatin, is highly effective in a human colon tumor model. J. Nat. Prod., 2008, 71, 321-324.
76. Stierle, A.; Strobel, G.; Stierle, D. Taxol and taxane production by Taxomyces andreanae, an endophytic fungus of Pacific yew. Science., 1993, 260, 214-216.
77. Li, J. Y.; Sidhu, R. S.; Bollon, A.; Strobel, G. A. Stimulation of taxol production in liquid cultures of Pestalotiopsis microspora. Mycol. Res., 1998, 102, 461-464.
78. Amna, T.; Puri, S. C.; Verma, V.; Sharma, J. P.; Khajuria, R. K.; Musarrat, J.; Spiteller, M.; Qazi, G. N. Bioreactor studies on the endophytic fungus Entrophospora infrequens for the production of an anticancer alkaloid camptothecin. Can. J. Microbiol., 2006, 52, 189-196.
79. Puri, S. G.; Verma, V.; Amna, T.; Qazi, G. N.; Spiteller, M. An endophytic fungus from Nothapodytes foetida that produces camptothecin. J. Nat. Prod., 2005, 68, 1717-1719.
80. Eyberger, A. L.; Dondapati, R.; Porter, J. R. Endophyte fungal isolates from Podophyllum peltatum produce podophyllotoxin. J. Nat. Prod., 2006, 69, 1121-1124.
81. Puri, S. C.; Nazir, A.; Chawla, R.; Arora, R.; Riyaz-Ul-Hasan, S.; Amna, T.; Ahmed, B.; Verma, V.; Singh, S.; Sagar, R.; Sharma, A.; Kumar, R.; Sharma, R. K.; Qazi, G. N. The endophytic fungus Trametes hirsuta as a novel alternative source of podophyllotoxin and related aryl tetralin lignans. J. Biotechnol., 2006, 122, 494-510.
82. Guo, B.; Li, H.; Zhang, L. Isolation of a fungus producing vinblastineIsolation of a fungus producing vinblastine. Yunnan Daxue Xuebao, Ziran Kexueban 1998, 20, 214-215.
83. Yang, X.; Zhang, L.; Guo, B.; Guo, S. Preliminary study of a vincristineproducing endophytic fungus isolated from leaves of Catharanthus roseusPreliminary study of a vincristine-producing endophytic fungus isolated from leaves of Catharanthus roseus. Zhong Cao Yao 2004, 35, 79-81.
84. Zhang, L.; Guo, B.; Li, H.; Zeng, S.; Shao, H.; Gu, S.; Wei, R., Isolation of endophytic fungus of Catharanthus roseus and its fermentation to produce products of therapeuticIsolation of endophytic fungus of Catharanthus roseus and its fermentation to produce products of therapeutic. Zhong Cao Yao 2000, 31, 805-807.
85. Bok, J. W.; Hoffmeister, D.; Maggio-Hall, L. A.; Murillo, R.; Glasner, J. D.; Keller, N. P. Genomic mining for Aspergillus natural products. Chem., Biol., 2006, 13, 31-37.
86. Chiang, Y.-M.; Szewczyk, E.; Nayak, T.; Davidson, A. D.; Sanchez, J. F.; Lo, H.-C.; Ho, W.-Y.; Simityan, H.; Kuo, E.; Praseuth, A.; Watanabe, K.; Oakley, B. R.; Wang, C. C. C. Molecular genetic mining of the Aspergillus secondary metabolome: discovery of the emericellamide biosynthetic pathway. Chem. Biol., 2008, 15, 527-532.
87. Brakhage, A. A.; Schuemann, J.; Bergmann, S.; Scherlach, K.; Schroeckh, V.; Hertweck, C. Activation of fungal silent gene clusters: a new avenue to drug discovery. Progr. Drug Res. Fort. 2008, 66, 1, 3-12.
88. Fox, E. M.; Howlett, B. J. Secondary metabolism: regulation and role in fungal biology. Curr. Opin. Microbiol., 2008, 11, 481-487.
89. Hoffmeister, D.; Keller, N. P. Natural products of filamentous fungi: enzymes, genes, and their regulation. Nat. Prod. Rep., 2007, 24, 393-416.
90. Stadler, M.; Keller, N. P. Paradigm shifts in fungal secondary metabolite research. Mycol. Res., 2008, 112, 127-130.
91. Horinouchi, S. Combinatorial biosynthesis of plant medicinal polyketides by microorganisms. Curr. Opin. Chem. Biol., 2009, 13, 197-204.
92. Funa, N.; Ohnishi, Y.; Fujii, I.; Shibuya, M.; Ebizuka, Y.; Horinouchi, S. A new pathway for polyketide synthesis in microorganisms. Nature., 1999, 400, 897-899.
93. Kaneko, M.; Ohnishi, Y.; Horinouchi, S. Cinnamate:coenzyme A ligase from the filamentous bacterium streptomyces coelicolor A3(2). J. Bacteriol., 2003, 185, 20-27.